Higher dose oral fluconazole for the treatment of AIDS-related cryptococcal meningitis (HIFLAC)--Report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

Authors

Umesh G. Lalloo, Durban University of Technology
David B. Clifford, Washington University School of Medicine in St. Louis
et al.

Journal

PLoS One

Publication Date

1-1-2023

Volume

18

Issue

2

First Page

e0281580

Document Type

Open Access Publication

DOI

10.1371/journal.pone.0281580

Rights and Permissions

Lalloo UG, Komarow L, Aberg JA, Clifford DB, Hogg E, et al. (2023) Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. PLOS ONE 18(2): e0281580. https://doi.org/10.1371/journal.pone.0281580. © 2023 Lalloo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Lalloo, Umesh G.; Clifford, David B.; and et al., "Higher dose oral fluconazole for the treatment of AIDS-related cryptococcal meningitis (HIFLAC)--Report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group." PLoS One. 18, 2. e0281580 (2023).
https://digitalcommons.wustl.edu/oa_4/1275

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.